Compare JPMorgan Chase & Co (JPM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Chase & Co trades at $364.94 (market cap $962.37B), while State Street SPDR S&P Biotech ETF trades at $159.07. The key difference: JPMorgan Chase & Co pays a 1.66% dividend while State Street SPDR S&P Biotech ETF pays none, and JPMorgan Chase & Co is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| JPM | XBI | |
|---|---|---|
Market Cap | $962.37B | — |
Volume | 10,479,943 | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $362.04 | $164.28 |
52-Week Low | $282.84 | $86.92 |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $365.11, up 1.48% in 24 hours, with a bullish technical signal and strong fundamentals including a 33.38% net income margin and 18.43% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Moderate Buy with a $374.18 price target. CEO Jamie Dimon's shareholder letter highlights economic risks, but institutional buying and resilient sector performance support optimism.
The outlook for JPM is positive, driven by earnings momentum and sector strength, though risks include geopolitical tensions and potential economic headwinds noted by management. Upside to the consensus target offers opportunity, but investors should weigh high RSI levels and macroeconomic cautions.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
